Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharma a/s - pantoprazolnatriumsesquihydrat - enterotabletter - 20 mg

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharma a/s - pantoprazolnatriumsesquihydrat - enterotabletter - 40 mg

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharma a/s - pantoprazolnatriumsesquihydrat - pulver til injektionsvæske, opløsning - 40 mg

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharma a/s - phenoxymethylpenicillinkalium - filmovertrukne tabletter - 1,5 mill. ie

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharma a/s - phenoxymethylpenicillinkalium - filmovertrukne tabletter - 1 mill. ie

Европейски съюз - датски - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioødemer, arvelige - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Европейски съюз - датски - EMA (European Medicines Agency)

baxalta innovations gmbh - vonicog alfa - von willebrand sygdomme - antihemorrhagics - veyvondi er indiceret hos voksne (18 år og ældre) med von willebrand sygdom (vwd), når desmopressin (ddavp) behandlingen alene er ineffektive eller ikke indiceret til behandling af blødning og kirurgisk blødning - forebyggelse af kirurgiske blødninger. veyvondi bør ikke anvendes i behandling af hæmofili a.

Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda manufacturing austria ag - alfa-1 proteinaseinhibitor, humant - pulver og solvens til infusionsvæske, opløsning - 1000 mg

Европейски съюз - датски - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirusinfektioner - antivirale midler til systemisk anvendelse - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antivirale agenter.

Европейски съюз - датски - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vacciner - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.